Research Summary
Liposomal doxorubicin is a drug formulation that involves encapsulating the chemotherapy drug doxorubicin within lipid bilayers, creating liposomes. These liposomes help the drug to be more targeted and delivered specifically to cancer cells.
The liposomal formulation allows for increased drug stability, improved pharmacokinetics, and reduced toxicity compared to the conventional form of doxorubicin. The liposomes protect the drug from degradation in the bloodstream, allowing for a longer circulation time and enhanced accumulation in tumor tissues.
Liposomal doxorubicin has been approved by the FDA for the treatment of several types of cancer, including ovarian cancer, breast cancer, and AIDS-related Kaposi's sarcoma. It is usually administered intravenously and is commonly used in combination with other chemotherapy drugs.
According to DIResearch's in-depth investigation and research, the global Liposomal Doxorubicin market size will reach US$ XX Million in 2024, and is expected to reach US$ XX Million in 2030, with a CAGR of XX% (2025-2030). Among them, the China market has changed rapidly in the past few years. The market size in 2024 will be US$ XX Million, accounting for approximately XX% of the world. It is expected to reach US$ XX Million in 2030, and the global share will reach XX%.
The major global manufacturers of Liposomal Doxorubicin include Johnson & Johnson, Sun Pharmaceutical, CSPC, Kinyond, Teva, Fudan-Zhangjiang, Zydus Cadila, TTY Biopharma etc. The global players competition landscape in this report is divided into three tiers. The first tiers is the global leading enterprise, which occupies a major market share, is in a leading position in the industry, has strong competitiveness and influence, and has a large revenue scale; the second tiers has a certain share and popularity in the market, actively follows the industry leaders in product, service or technological innovation, and has a medium revenue scale; the third tiers has a smaller share in the market, has a lower brand awareness, mainly focuses on the local market, and has a relatively small revenue scale.
This report studies the market size, price trends and future development prospects of Liposomal Doxorubicin. Focus on analysing the market share, product portfolio, prices, sales volume, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Liposomal Doxorubicin market. The report data covers historical data from 2019 to 2023, based year in 2024 and forecast data from 2025 to 2030.
The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Liposomal Doxorubicin market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Liposomal Doxorubicin industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Manufacturers of Liposomal Doxorubicin Include:
Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
Liposomal Doxorubicin Product Segment Include:
5 ml
10 ml
25 ml
Liposomal Doxorubicin Product Application Include:
Breast Cancer
Liver Cancer
Kidney Cancer
Multiple Myeloma
Ovarian Cancer
Other
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends
Chapter 2: Global Liposomal Doxorubicin Industry PESTEL Analysis
Chapter 3: Global Liposomal Doxorubicin Industry Porter's Five Forces Analysis
Chapter 4: Global Liposomal Doxorubicin Major Regional Market Size (Revenue, Sales, Price) and Forecast Analysis
Chapter 5: Global Liposomal Doxorubicin Market Size and Forecast by Type and Application Analysis
Chapter 6: North America Liposomal Doxorubicin Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 7: Europe Liposomal Doxorubicin Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 8: China Liposomal Doxorubicin Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 9: APAC (Excl. China) Liposomal Doxorubicin Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 10: Latin America Liposomal Doxorubicin Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 11: Middle East and Africa Liposomal Doxorubicin Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)
Chapter 12: Global Liposomal Doxorubicin Competitive Analysis of Key Manufacturers (Sales, Revenue, Market Share, Price, Regional Distribution and Industry Concentration)
Chapter 13: Key Company Profiles (Product Portfolio, Sales, Revenue, Price and Gross Margin)
Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers
Chapter 15: Research Findings and Conclusion
Chapter 16: Methodology and Data Sources
Table of Contents 1 Liposomal Doxorubicin Market Overview 1.1 Product Definition and Statistical Scope 1.2 Liposomal Doxorubicin Product by Type 1.2.1 Global Liposomal Doxorubicin Market Size by Type, 2023 VS 2024 VS 2030 1.2.2 5 ml 1.2.3 10 ml 1.2.4 25 ml 1.3 Liposomal Doxorubicin Product by Application 1.3.1 Global Liposomal Doxorubicin Market Size by Application, 2023 VS 2024 VS 2030 1.3.2 Breast Cancer 1.3.3 Liver Cancer 1.3.4 Kidney Cancer 1.3.5 Multiple Myeloma 1.3.6 Ovarian Cancer 1.3.7 Other 1.4 Global Liposomal Doxorubicin Market Revenue and Sales Analysis 1.4.1 Global Liposomal Doxorubicin Market Size Analysis (2019-2030) 1.4.2 Global Liposomal Doxorubicin Market Sales Analysis (2019-2030) 1.4.3 Global Liposomal Doxorubicin Market Sales Price Trend Analysis (2019-2030) 1.5 Liposomal Doxorubicin Market Development Status and Trends 1.5.1 Liposomal Doxorubicin Industry Development Status Analysis 1.5.2 Liposomal Doxorubicin Industry Development Trends Analysis 2 Liposomal Doxorubicin Market PESTEL Analysis 2.1 Political Factors Analysis 2.2 Economic Factors Analysis 2.3 Social Factors Analysis 2.4 Technological Factors Analysis 2.5 Environmental Factors Analysis 2.6 Legal Factors Analysis 3 Liposomal Doxorubicin Market Porter's Five Forces Analysis 3.1 Competitive Rivalry 3.2 Threat of New Entrants 3.3 Bargaining Power of Suppliers 3.4 Bargaining Power of Buyers 3.5 Threat of Substitutes 4 Global Liposomal Doxorubicin Market Analysis by Regions 4.1 Liposomal Doxorubicin Overall Market: 2023 VS 2024 VS 2030 4.2 Global Liposomal Doxorubicin Revenue and Forecast Analysis (2019-2030) 4.2.1 Global Liposomal Doxorubicin Revenue and Market Share by Region (2019-2024) 4.2.2 Global Liposomal Doxorubicin Revenue Forecast by Region (2025-2030) 4.3 Global Liposomal Doxorubicin Sales and Forecast Analysis (2019-2030) 4.3.1 Global Liposomal Doxorubicin Sales and Market Share by Region (2019-2024) 4.3.2 Global Liposomal Doxorubicin Sales Forecast by Region (2025-2030) 4.4 Global Liposomal Doxorubicin Sales Price Trend Analysis (2019-2030) 5 Global Liposomal Doxorubicin Market Size by Type and Application 5.1 Global Liposomal Doxorubicin Market Size by Type 5.1.1 Global Liposomal Doxorubicin Revenue and Forecast Analysis by Type (2019-2030) 5.1.2 Global Liposomal Doxorubicin Sales and Forecast Analysis by Type (2019-2030) 5.2 Global Liposomal Doxorubicin Market Size by Application 5.2.1 Global Liposomal Doxorubicin Revenue and Forecast Analysis by Application (2019-2030) 5.2.2 Global Liposomal Doxorubicin Sales and Forecast Analysis by Application (2019-2030) 6 North America 6.1 North America Liposomal Doxorubicin Market Size and Growth Rate Analysis (2019-2030) 6.2 North America Key Manufacturers Analysis 6.3 North America Liposomal Doxorubicin Market Size by Type 6.3.1 North America Liposomal Doxorubicin Sales by Type (2019-2030) 6.3.2 North America Liposomal Doxorubicin Revenue by Type (2019-2030) 6.4 North America Liposomal Doxorubicin Market Size by Application 6.4.1 North America Liposomal Doxorubicin Sales by Application (2019-2030) 6.4.2 North America Liposomal Doxorubicin Revenue by Application (2019-2030) 6.5 North America Liposomal Doxorubicin Market Size by Country 6.5.1 US 6.5.2 Canada 7 Europe 7.1 Europe Liposomal Doxorubicin Market Size and Growth Rate Analysis (2019-2030) 7.2 Europe Key Manufacturers Analysis 7.3 Europe Liposomal Doxorubicin Market Size by Type 7.3.1 Europe Liposomal Doxorubicin Sales by Type (2019-2030) 7.3.2 Europe Liposomal Doxorubicin Revenue by Type (2019-2030) 7.4 Europe Liposomal Doxorubicin Market Size by Application 7.4.1 Europe Liposomal Doxorubicin Sales by Application (2019-2030) 7.4.2 ? Europe Liposomal Doxorubicin Revenue by Application (2019-2030) 7.5 Europe Liposomal Doxorubicin Market Size by Country 7.5.1 Germany 7.5.2 France 7.5.3 United Kingdom 7.5.4 Italy 7.5.5 Spain 7.5.6 Benelux 8 China 8.1 China Liposomal Doxorubicin Market Size and Growth Rate Analysis (2019-2030) 8.2 China Key Manufacturers Analysis 8.3 China Liposomal Doxorubicin Market Size by Type 8.3.1 China Liposomal Doxorubicin Sales by Type (2019-2030) 8.3.2 China Liposomal Doxorubicin Revenue by Type (2019-2030) 8.4 China Liposomal Doxorubicin Market Size by Application 8.4.1 China Liposomal Doxorubicin Sales by Application (2019-2030) 8.4.2 China Liposomal Doxorubicin Revenue by Application (2019-2030) 9 APAC (excl. China) 9.1 APAC (excl. China) Liposomal Doxorubicin Market Size and Growth Rate Analysis (2019-2030) 9.2 APAC (excl. China) Key Manufacturers Analysis 9.3 APAC (excl. China) Liposomal Doxorubicin Market Size by Type 9.3.1 APAC (excl. China) Liposomal Doxorubicin Sales by Type (2019-2030) 9.3.2 APAC (excl. China) Liposomal Doxorubicin Revenue by Type (2019-2030) 9.4 APAC (excl. China) Liposomal Doxorubicin Market Size by Application 9.4.1 APAC (excl. China) Liposomal Doxorubicin Sales by Application (2019-2030) 9.4.2 APAC (excl. China) Liposomal Doxorubicin Revenue by Application (2019-2030) 9.5 APAC (excl. China) Liposomal Doxorubicin Market Size by Country 9.5.1 Japan 9.5.2 South Korea 9.5.3 India 9.5.4 Australia 9.5.5 Indonesia 9.5.6 Vietnam 9.5.7 Malaysia 9.5.8 Thailand 10 Latin America 10.1 Latin America Liposomal Doxorubicin Market Size and Growth Rate Analysis (2019-2030) 10.2 Latin America Key Manufacturers Analysis 10.3 Latin America Liposomal Doxorubicin Market Size by Type 10.3.1 Latin America Liposomal Doxorubicin Sales by Type (2019-2030) 10.3.2 Latin America Liposomal Doxorubicin Revenue by Type (2019-2030) 10.4 Latin America Liposomal Doxorubicin Market Size by Application 10.4.1 Latin America Liposomal Doxorubicin Sales by Application (2019-2030) 10.4.2 Latin America Liposomal Doxorubicin Revenue by Application (2019-2030) 10.5 Latin America Liposomal Doxorubicin Market Size by Country 10.5.1 Mexico 10.5.2 Brazil 11 Middle East & Africa 11.1 Middle East & Africa Liposomal Doxorubicin Market Size and Growth Rate Analysis (2019-2030) 11.2 Middle East & Africa Key Manufacturers Analysis 11.3 Middle East & Africa Liposomal Doxorubicin Market Size by Type 11.3.1 Middle East & Africa Liposomal Doxorubicin Sales by Type (2019-2030) 11.3.2 Middle East & Africa Liposomal Doxorubicin Revenue by Type (2019-2030) 11.4 Middle East & Africa Liposomal Doxorubicin Market Size by Application 11.4.1 Middle East & Africa Liposomal Doxorubicin Sales by Application (2019-2030) 11.4.2 Middle East & Africa Liposomal Doxorubicin Revenue by Application (2019-2030) 11.5 Middle East & Africa Liposomal Doxorubicin Market Size by Country 11.5.1 Saudi Arabia 11.5.2 South Africa 12 Competition by Manufacturers 12.1 Global Liposomal Doxorubicin Market Sales, Revenue and Price by Key Manufacturers (2020-2024) 12.1.1 Global Liposomal Doxorubicin Market Sales by Key Manufacturers (2020-2024) 12.1.2 Global Liposomal Doxorubicin Market Revenue by Key Manufacturers (2020-2024) 12.1.3 Global Liposomal Doxorubicin Average Sales Price by Manufacturers (2020-2024) 12.2 Liposomal Doxorubicin Competitive Landscape Analysis and Market Dynamic 12.2.1 Liposomal Doxorubicin Competitive Landscape Analysis 12.2.2 Global Key Manufacturers Headquarter Location and Key Area Sales 12.2.3 Market Dynamic 13 Key Companies Analysis 13.1 Johnson & Johnson 13.1.1 Johnson & Johnson Basic Company Profile (Employees, Areas Service, Competitors and Contact Information) 13.1.2 Johnson & Johnson Liposomal Doxorubicin Product Portfolio 13.1.3 Johnson & Johnson Liposomal Doxorubicin Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2020-2024) 13.2 Sun Pharmaceutical 13.2.1 Sun Pharmaceutical Basic Company Profile (Employees, Areas Service, Competitors and Contact Information) 13.2.2 Sun Pharmaceutical Liposomal Doxorubicin Product Portfolio 13.2.3 Sun Pharmaceutical Liposomal Doxorubicin Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2020-2024) 13.3 CSPC 13.3.1 CSPC Basic Company Profile (Employees, Areas Service, Competitors and Contact Information) 13.3.2 CSPC Liposomal Doxorubicin Product Portfolio 13.3.3 CSPC Liposomal Doxorubicin Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2020-2024) 13.4 Kinyond 13.4.1 Kinyond Basic Company Profile (Employees, Areas Service, Competitors and Contact Information) 13.4.2 Kinyond Liposomal Doxorubicin Product Portfolio 13.4.3 Kinyond Liposomal Doxorubicin Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2020-2024) 13.5 Teva 13.5.1 Teva Basic Company Profile (Employees, Areas Service, Competitors and Contact Information) 13.5.2 Teva Liposomal Doxorubicin Product Portfolio 13.5.3 Teva Liposomal Doxorubicin Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2020-2024) 13.6 Fudan-Zhangjiang 13.6.1 Fudan-Zhangjiang Basic Company Profile (Employees, Areas Service, Competitors and Contact Information) 13.6.2 Fudan-Zhangjiang Liposomal Doxorubicin Product Portfolio 13.6.3 Fudan-Zhangjiang Liposomal Doxorubicin Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2020-2024) 13.7 Zydus Cadila 13.7.1 Zydus Cadila Basic Company Profile (Employees, Areas Service, Competitors and Contact Information) 13.7.2 Zydus Cadila Liposomal Doxorubicin Product Portfolio 13.7.3 Zydus Cadila Liposomal Doxorubicin Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2020-2024) 13.8 TTY Biopharma 13.8.1 TTY Biopharma Basic Company Profile (Employees, Areas Service, Competitors and Contact Information) 13.8.2 TTY Biopharma Liposomal Doxorubicin Product Portfolio 13.8.3 TTY Biopharma Liposomal Doxorubicin Market Data Analysis (Revenue, Sales, Price, Gross Margin and Market Share) (2020-2024) 14 Industry Chain Analysis 14.1 Liposomal Doxorubicin Industry Chain Analysis 14.2 Liposomal Doxorubicin Industry Upstream Supply Analysis 14.2.1 Upstream Key Raw Material Supply Analysis 14.2.2 Raw Material Suppliers and Contact Information 14.3 Liposomal Doxorubicin Typical Downstream Customers 14.4 Liposomal Doxorubicin Sales Channel Analysis 15 Research Findings and Conclusion 16 Methodology and Data Source 16.1 Methodology/Research Approach 16.2 Research Scope 16.3 Benchmarks and Assumptions 16.4 Date Source 16.4.1 Primary Sources 16.4.2 Secondary Sources 16.5 Data Cross Validation 16.6 Disclaimer
Publisher: DIResearch
Related Reports
- Global Epilepsy Therapeutics Market (2024 Edition): Analysis By Generation (First Generation, Second Generation, Third Generation), By Route of Administration, By Type, By Region, By Country: Market Insights and Forecast (2020-2030)
- Global Online Pharmacy Market (2024 Edition): Analysis By Drug Type (Over the Counter (OTC) Drugs, Prescription Drugs, Others), By Platform, By Product Type, By Region: Market Insights and Forecast (2020-2030)
- Global Diagnostic X-rays Market (2024 Edition): Analysis By Type (General Radiography, Angiography, Surgical Fluoroscopy, Mobile X ray, Other Types), By End Users, By Region, By Country: Market Insights and Forecast (2020-2030)
- Global Diagnostic Labs Market (2024 Edition): Analysis By Testing Services (Physiological Function Testing, General and Clinical Testing, Esoteric Testing, Specialized Testing, and Others), By Lab Type, By Application: Market Insights and Forecast (2020-2030)
- Lateral Flow Assays Market By Product Type (Lateral Flow Readers {Digital/Mobile Readers and Benchtop Readers} and Kits and Reagents), By Application (Clinical Testing {Pregnancy Testing, Influenza Testing, Tuberculosis, D-Dimer Testing, and Other Clinical Testing}, Drug Abuse Testing, Veterinary Diagnostics, Food Safety & Environmental Testing, and Other Applications), By Technique (Sandwich Assay, Competitive Assay, and Multiplex Assay), By End-User (Home Care, Hospitals and Clinics, and Other End Users), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 - 2035
Why Market Study Report?
- Best Price for Reports
- Large Report Database
- Easily Customize Reports
- 24/7 Email & Phone Support